(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 August 2011 (18.08.2011)

PCT

(10) International Publication Number
WO 2011/098520 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/EP2011/051958

(22) International Filing Date:
10 February 2011 (10.02.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/303,173 10 February 2010 (10.02.2010) US
61/308,599 26 February 2010 (26.02.2010) US

(71) Applicants *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **ABLYNX NV** [BE/BE]; Technologiepark 4, B-9052 Zwijnaarde (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CROMIE, Karen** [GB/BE]; Ablynx NV, Technologiepark 4, B-9052 Zwijnaarde (BE). **DOMBRECHT, Bruno** [BE/BE]; Ablynx NV, Technologiepark 4, B-9052 Zwijnaarde (BE). **ETTENBERG, Seth** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **KOLKMAN, Joost** [NL/BE]; Ablynx NV, Technologiepark 4, B-9052 Zwijnaarde (BE). **LI, Jing** [US/US]; Novartis Institutes for BioMedical Research, Inc., 200 Technology Square, Cambridge, Massachusetts 02139 (US). **MEERSCHAERT, Kris** [BE/BE]; Ablynx NV, Technologiepark 4, B-9052 Zwijnaarde (BE). **STOVER, David Raymond** [US/US]; 15093 Hesby ST, Sherman Oaks, California 91403 (US). **ZHANG, Jingxin** [CN/US]; 8 Shoreview Lane, Walpole, Massachusetts 02081 (US).

(74) Agent: **KASSOW, Anders**; NOVARTIS PHARMA AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

[Continued on next page]

(54) Title: AGONIST DR5 BINDING POLYPEPTIDES




FIGURE 6B

(57) Abstract: The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also "DR5"), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as "NB agents") and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.

WO 2011/098520 A1

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *with sequence listing part of description (Rule 5.2(a))*

Published:

— *with international search report (Art. 21(3))*